Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder

• Status: Completed
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The study will compare the effectiveness of antipsychotic medications for patients with schizophrenia or schizoaffective disorder for whom a medication change may be indicated because of an increased risk of cardiovascular disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Mental Health (NIMH)
• Treatments: Antipsychotic Agents; Aripiprazole; Olanzapine; Quetiapine Fumarate; Risperidone

Criteria

Inclusion Criteria:

• Diagnosed with schizophrenia or schizoaffective disorder

• Currently treated with olanzapine, quetiapine or risperidone

• BMI greater than or equal to 27

• Non-HDL cholesterol greater than or equal to 130 mg/dL (if non-HDL cholesterol is between 130 - 139 mg/dL, then LDL cholesterol must be greater than 100 mg/dL).

Exclusion Criteria:

• Diabetes (FBS greater than or equal to 126) or treatment with oral hypoglycemic drug or insulin

• Non-HDL cholesterol greater than 300 mg/dL

• Serum triglycerides greater than 500 mg/dL

• Patients in the first episode of schizophrenia or schizoaffective disorder

• Known hypersensitivity to aripiprazole

• On weight loss medications